A
RCUS
Arcus Bioscience
22.07
-0.17-0.76%Pre Market: 22.30 +0.23 +1.04%08:45 04/08 EDT
OPEN/PREV CLOSE22.15/22.24
TODAY RANGE21.59-22.32
VOL57
MARKET CAP2.77B
52 WEEK RANGE6.50-26.40
AVG VOL (3M)1.22M
% TURNOVER0.57%
TURNOVER0
P/E (TTM)-6.7147
% RANGE3.26%
EPS(TTM)-3.2868
P/E(FORWARD)-5.9169
P/B4.383
BVPS5.04
DIVIDEND--
P/S11.20
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP1.94B
SHARES OUTSTANDING125.35M
NEXT EARNINGS05/04-05/08
FREE FLOAT88.04M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Dow Jones·5d ago
Arcus Biosciences Is Maintained at Outperform by Wedbush
Simply Wall St·03/27 23:07
Assessing Arcus Biosciences (RCUS) Valuation After Recent Share Price Weakness And Strong One Year Rebound
TipRanks·03/24 15:25
Mizuho Securities Remains a Buy on Arcus Biosciences (RCUS)
Dow Jones·03/23 12:37
Damora Therapeutics Names Jennifer Jarrett as CEO
TipRanks·03/23 12:24
Arcus Biosciences Announces COO Resignation and Transition Plan
TipRanks·03/23 12:15
Damora Therapeutics appoints Jennifer Jarrett as CEO
Simply Wall St·03/11 00:37
Why Arcus Biosciences (RCUS) Is Up 9.5% After New Casdatifan Data And Pipeline Expansion
Simply Wall St·03/09 08:12
Arcus Biosciences (RCUS) Valuation After Casdatifan Kidney Cancer Data Pipeline Update And Earnings
Simply Wall St·03/06 02:34
Arcus Biosciences Casdatifan Data Reshapes Kidney Cancer And Valuation Story
Dow Jones·03/05 19:43
Arcus Biosciences Price Target Raised to $45.00/Share From $44.00 by Citigroup
Dow Jones·03/05 19:43
Arcus Biosciences Is Maintained at Buy by Citigroup
Benzinga·03/05 19:34
Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $45
Same Industry
Name/Symbol
Change%
Price